Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection

Brahm H Segal; Lisa A Barnhart; Victoria L Anderson; Thomas J Walsh; Harry L Malech; Steven M Holland

doi:10.1086/430068

Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection

Clin Infect Dis. 2005 Jun 1;40(11):1684-8. doi: 10.1086/430068. Epub 2005 Apr 29.

Authors

Brahm H Segal¹, Lisa A Barnhart, Victoria L Anderson, Thomas J Walsh, Harry L Malech, Steven M Holland

Affiliation

¹ Department of Medicine, Division of Infectious Diseases, Roswell Park Cancer Institute, Buffalo, NY, USA.

PMID: 15889369
DOI: 10.1086/430068

Abstract

Chronic granulomatous disease (CGD) is characterized by life-threatening bacterial and fungal infections. Treatment with posaconazole led to a complete response in 7 of 8 patients with CGD with invasive mold infections (7 proven cases and 1 possible case) after failure or intolerance of treatment with standard antifungal agents. In this preliminary study, salvage treatment with posaconazole was safe and effective.

Publication types

Clinical Trial

MeSH terms

Adolescent
Adult
Antifungal Agents / therapeutic use*
Child
Female
Fungi / isolation & purification*
Fungi / pathogenicity
Granulomatous Disease, Chronic / complications*
Humans
Lung Diseases, Fungal / complications*
Lung Diseases, Fungal / drug therapy*
Lung Diseases, Fungal / genetics
Lung Diseases, Fungal / microbiology
Male
Salvage Therapy*
Triazoles / therapeutic use*

Substances

Antifungal Agents
Triazoles
posaconazole